De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial?
| Autor: | Amira Al Balakosy, Iman F. Montasser, Amany M.A. Ibrahim, Hoda M. Farid |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Liver Cirrhosis
medicine.medical_specialty Carcinoma Hepatocellular Hepatitis C virus Hepacivirus medicine.disease_cause Group A Gastroenterology Antiviral Agents Group B Lesion 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Hepatology Tumor size business.industry Significant difference Liver Neoplasms Hepatitis C Chronic medicine.disease Hepatitis C Portal vein thrombosis 030220 oncology & carcinogenesis Hepatocellular carcinoma 030211 gastroenterology & hepatology medicine.symptom business |
| Zdroj: | Clinics and research in hepatology and gastroenterology. 45(4) |
| ISSN: | 2210-741X |
| Popis: | Summary Background and aim Behavior of HCC that developed after DAAs therapy for HCV infection is still debated. In this study we aim to compare characteristics and pattern of de novo HCC in cirrhotic HCV patients who were treated and untreated with DAAs. Patients and methods This study included 160 cirrhotic HCV patients presented with de novo HCC during the period of December 2017 to December 2018. Patients were divided into two groups, group A included 80 patients who received DAAs and group B included 80 patients who were not exposed to DAAs. The characteristics of HCC in both groups were compared using BCLC Staging System. Results The size of the largest lesion was 47 mm ± 26 in group A and 41 mm ± 27 in group B with statistically significant difference between both groups (p = 0.03). No other significant differences existed regarding number, site, or total tumor size and most of the lesions were solid in both groups. Portal vein thrombosis and extrahepatic spread detected in 16 and 11 patients in group A, while in group B the number was 17 and 9 patients respectively (p = 0.83 and 0.06). No significant differences between groups in type of intervention done, BCLC staging (p = 0.4), or survival. Conclusion Although CHCV patients treated with DAAs had larger de novo HCC lesions than untreated patients, there was no difference in BCLC staging or in aggressive behavior between both groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect